2096 — Simcere Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Simcere Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	PRESS	PRESS
Standards:	IFRS	IFRS	IFRS	—	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,000	6,324	6,608	6,635	7,731
Cost of Revenue
Gross Profit	3,920	4,997	4,984	5,325	6,310
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,551	5,463	5,896	5,799	6,176
Operating Profit	1,449	861	712	836	1,555
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	1,402	886	740	809	1,514
Provision for Income Taxes
Net Income After Taxes	1,499	927	714	722	1,344
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,507	931	715	722	1,344
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	1,507	931	715	733	1,344
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.477	0.358	0.085	0.292	0.547
Dividends per Share